close

IT incident update – 28 March 2024

Following the IT outage we suffered yesterday (Wednesday 27 March), the majority of our systems have now been restored overnight.

The Christie Hotline (0161 446 3658) and switchboard (0161 446 3000) are working so patients can contact us as normal in this way.

We will continue to post information on the Trust website and social media channels with any further updates as necessary.

If you are attending for an appointment today, please bring with you information about your treatment, past medical history and medications which will help our staff should any systems still be slow. We apologise for any delays that this incident may cause to your care and treatment.

Skip to Content

Clinical trials in T-Cell lymphoma

The list below shows The Lymphoma Group's current clinical trials open for recruitment for T-Cell lymphoma patients.

If you would like to know how to access our trials, please see how to contact us.

  • PROCLIPI - A non-medicinal (observational) clinical trial involving collecting data on patients with mycosis fungoides (primary cutaneous T cell lymphoma) and Sézary syndrome (SS), to help determine how we manage future patients.A non-medicinal (observational) clinical trial involving collecting data on patients with mycosis fungoides (primary cutaneous T cell lymphoma) and Sézary syndrome (SS), to help determine how we manage future patients.
  • SGN35-032 - A phase 2 trial of brentuximab vedotin plus chemotherapy in people with peripheral T-cell lymphoma.
  • StepPharma/STP938 – Testing STP938 in people with T-cell and B-cell lymphomas that has relapsed or is refractory

  • ASTX660-003 – Testing Tolinapant in combination with other drugs in patients with relapsed or refractory PTCL

  • CCS1477 – Testing CCS1477 in blood cancers, including relapsed or refractory non-Hodgkin lymphoma

With special thanks to the following:

Lymphoma actionCancer Research UKBloodwiseNCRI

For further information on each trial, please visit the Find a trial page on Lymphoma Action’s website.

Last updated: October 2023